Galili, Naomi <br/><br/>
Immunomodulatory drugs in myelodysplastic syndromes.  [electronic resource] 

 -  Expert opinion on investigational drugs  Jul 2006 
 - 805-13 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1744-7658 
<br/><br/><label>Standard No.: </label>10.1517/13543784.15.7.805  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--adverse effects<br/>Animals<br/>Apoptosis--drug effects<br/>Blood Transfusion<br/>Cell Lineage<br/>Cells, Cultured--drug effects<br/>Chromosome Deletion<br/>Chromosomes, Human, Pair 5--ultrastructure<br/>Clinical Trials as Topic<br/>Cytokines--physiology<br/>Drug Evaluation, Preclinical<br/>Drugs, Investigational--therapeutic use<br/>Erythrocyte Transfusion<br/>Erythropoiesis--drug effects<br/>Female<br/>Hematopoietic Stem Cells--drug effects<br/>Humans<br/>Immunologic Factors--adverse effects<br/>Lenalidomide<br/>Male<br/>Middle Aged<br/>Myelodysplastic Syndromes--drug therapy<br/>NF-kappa B--antagonists & inhibitors<br/>Neutropenia--chemically induced<br/>Pilot Projects<br/>Thalidomide--adverse effects<br/>Thrombocytopenia--chemically induced<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors